+/− mice also decreased albuminuria, although they exhibited comparable systolic blood pressure, sympathetic nerve activity and creatinine clearance to diabetic Ca v 2.2 +/+ mice. Consistently, diabetic mice with cilnidipine, an N-/L-type calcium channel blocker, showed a reduction in albuminuria and improvement of glomerular changes compared to diabetic mice with nitrendipine. In cultured podocytes, depolarization-dependent calcium responses were decreased by ω-conotoxin, a Ca v 2.2-specific inhibitor. Furthermore, reduction of nephrin by transforming growth factor-β (TGF-β) in podocytes was abolished with ω-conotoxin, cilnidipine or mitogen-activated protein kinase kinase inhibitor. In conclusion, Ca v 2.2 inhibition exerts renoprotective effects against the progression of diabetic nephropathy, partly by protecting podocytes.
Scientific RepoRts | 6:27192 | DOI: 10.1038/srep27192 channels are localized in the plasma membrane and are essential for the release of neurotransmitters and hormones 5 . These channels are classified into L-, P/Q-, N-, R-, and T-type subtypes based on their pharmacological and electrophysiological properties. Molecular biological analysis has shown that calcium channels are composed of α 1, α 2/δ , β , and γ subunits 6 , among which α 1 subunits are most important for defining channel properties. The α 1 subunit genes have been cloned and classified into the following three subfamilies based on their sequence similarity: Ca v 1.x, Ca v 2.x, and Ca v 3.x 7 . The α 1b subunit Ca v 2.2, encoded by the CACNA1B gene, is the only subunit which constitutes the N-type calcium channel.
Cilnidipine is an L-/N-type CCB which is used for patients with hypertension 8 . In several clinical 9-11 and basic [12] [13] [14] studies, cilnidipine has been shown to reduce proteinuria compared with other antihypertensive drugs. The CARTER study demonstrated that the L-/N-type CCB cilnidipine, but not the L-type CCB amlodipine, decreases urinary protein levels in RAS inhibitor-treated hypertensive patients with macroproteinuria 11 . The renoprotective effects of L-/N-type CCBs are at least partly due to the amelioration of glomerular hypertension 15 . L-type CCBs elicit afferent arteriole-prone vasodilation, which may increase the intraglomerular pressure 15 . On the other hand, L-/N-type CCBs ameliorate glomerular hypertension through the vasodilation of both afferent and efferent arterioles 16 . The N-type calcium channel α 1 subunit knockout (Ca v 2.2 −/− ) mice, which lack the cytosolic portion of the N-type calcium channel, are viable and have an almost normal behavior but show a very low sympathetic nerve activity in atria 17 . Although previous reports used cilnidipine to inhibit N-and L-type calcium channel in diabetic nephropathy, molecular mechanisms of specific N-type calcium channel blockade in glomerular injury are not fully investigated. To address these questions, we investigated renal injury in N-type calcium channel-deficient db/db mice on the diabetes-prone C57BLKS/J background. In addition, we examined the functional role of N-type calcium channel in cultured podocytes.
Results

Characteristics of Diabetic Ca v 2.2
−/− Mice. To examine the role of the N-type calcium channel in diabetic nephropathy, we crossed Ca v 2.2 −/− mice with db/m mice on the C57BLKS/J background more than six times to obtain db/db Ca v 2.2 −/− mice. All diabetic (db/db) mouse groups showed significantly increased body weights compared with those of non-diabetic (db/+ ) controls, and db/db Ca v 2.2 −/− mice tended to have a heavier body weight than other db/db mouse groups (Fig. 1a) . db/db Ca v 2.2 +/+ mice showed renal hypertrophy, as indicated by an increase in kidney weight, whereas db/db Ca v 2.2 −/− mice exhibited less renal hypertrophy (Fig. 1b) . We measured the systolic blood pressure (SBP) of db/+ mice at 8, 12 −/− mice, we analyzed 6-h fasting blood glucose levels every 2 weeks during the experimental period. All db/db mouse groups showed hyperglycemia at 8 weeks of age, whereas all db/+ mouse groups had normal glucose levels (Fig. 2a) . Notably, db/db Ca v 2.2 −/− mice had or tended to have lower levels of blood glucose than db/db Ca v 2.2 +/+ mice during the experimental period (Fig. 2a) . Sixteen-hour fasting serum insulin levels were not different among db/db mouse groups at 16 weeks of age (Fig. 2b) (Fig. 2e) . Serum insulin levels of db/db mouse groups in GTTs were increased compared with those of db/+ mouse groups (Fig. 2f) (Fig. 3a) . These results suggest that even a partial ablation of the N-type calcium channel leads to reduction in urinary albumin excretion.
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Next, we examined the effect of N-type calcium channel ablation on hyperfiltration induced by diabetic milieu by measuring CCr. Basal levels of serum creatinine were not different regardless of the genotype of Ca v 2.2 (Fig. 3b) (Fig. 3d ). Double immunohistochemical staining showed that cells positive for Ca v 2.2 in a glomerulus were also positive for WT1, a podocyte marker, indicating that Ca v 2.2 is expressed in podocytes (Fig. 3e) . We examined renal histology at 16 weeks of age. We observed mesangial expansion with glomerular hypertrophy in db/db Ca v 2.2 +/+ mice, which was consistent with diabetic alterations (Fig. 4a) (Fig. 4b) . These results suggest that N-type calcium channel ablation can limit the progression of diabetic nephropathy. Next, we evaluated podocyte injury in these mice. Immunostaining of nephrin and podocin, expressed predominantly in podocytes, was markedly decreased in db/db Ca v 2.2 +/+ mice compared with that in db/+ Ca v 2.2 +/+ mice (Fig. 4c) . In contrast, db/db Ca v 2.2 −/− mice maintained the expression of nephrin and podocin to the same level as db/+ mice, indicating the amelioration of podocyte injury (Fig. 4c) . In electron microscopic analysis, db/db Ca v 2.2 +/+ mice showed thickening of the glomerular basement membrane (GBM) with slightly widened podocyte foot processes (Fig. 4d,e) . GBM thickening was significantly ameliorated in db/db Ca v 2.2 −/− mice (Fig. 4e) . (Fig. 5a,b) . Expression of pro-alpha 3 chain of collagen IV (Col4a3) mRNA was also significantly reduced in db/db Ca v 2.2 −/− mice compared with db/db Ca v 2.2 +/+ mice (Fig. 5c ). Gene expression of fibronectin (Fn1) and pro-alpha 1 chain of collagen I (Col1a1) tended to decrease in db/db Ca v 2.2 −/− mice ( Supplementary Fig. S1a,b (Fig. 5e ). Glomerular expression of Cana1g, α 1 subunit of T-type calcium channel was upregulated in diabetic mice, and was not different among diabetic or non-diabetic 3 groups (Fig. 5f ). Activation of extracellular signal-regulated kinase (ERK) has been shown to mediate TGF-β -induced accumulation of ECM protein in diabetic nephropathy 18 . We found that ERK phosphorylation was increased in glomeruli, including mesangial cells and podocytes, of db/db Ca v 2.2 +/+ mice compared with that of db/+ Ca v 2.2 +/+ mice (Fig. 6a) . Phosphorylation of ERK was significantly lower in the glomeruli of db/db Ca v 2.2 −/− mice than db/ db Ca v 2.2 +/+ mice (Fig. 6a) . Macrophages also play a critical role in the progression of diabetic nephropathy 19 . The immunohistochemical study showed that macrophage antigen-2 (Mac2)-positive cells in glomeruli increased by 3.0-fold in db/db Ca v 2.2 +/+ mice compared with those in db/+ Ca v 2.2 +/+ mice (Fig. 6b,c) . This increase was significantly suppressed in db/db Ca v 2.2 −/− mice (Fig. 6b,c) .
Glomerular Gene Expression and Phosphorylation of Extracellular
Pharmacological Inhibition of L-or N-type Calcium Channel Ameliorates Diabetic
Nephropathy. (Fig. 2a, Supplementary Table S1 ). Diabetic mice with nitrendipine exhibited high urinary noradrenaline and adrenaline excretion, however, diabetic mice with cilnidipine did not change urinary catecholamine levels compared with those with nitrendipine ( Supplementary Fig. S2b,c) . Administration of nitrendipine or cilnidipine showed SBP almost similar to that in the vehicle and db/db Ca v 2.2 +/− mouse groups (Fig. 1d, Supplementary  Fig. S3a ). Diabetic Ca v 2.2 −/− mice showed lower SBP than vehicle, nitrendipine-, cilnidipine-treated and db/db Ca v 2.2 +/− mice (Fig. 1d, Supplementary Fig. S3a ). Urinary albumin excretion was suppressed in the cilnidipine-treated group and not in the nitrendipine-treated group, however, urinary albumin excretion in cilnidipine-treated mice was still higher than that in db/db Ca v 2.2 +/− mice ( Supplementary Fig. S3b ). Renal histology showed that treatment with cilnidipine, but not with nitrendipine, inhibited mesangial expansion in diabetic mice to the comparable extent of db/db Ca v 2.2 +/− mice ( Supplementary Fig. S3c,d) . In electron microscopic analysis, footprocesses widening and GBM thickening in diabetic mice was ameliorated only by cilnidipine treatment, which was comparable to db/db Ca v 2.2 −/− mice ( Supplementary Fig. S3e,f) . Glomerular expression of TGF-β 1 (Tgfb1) and connective tissue growth factor (Ctgf) mRNA tended to show a reduction in cilnidipine-treated mice, but the difference was not significant (Supplementary Fig. S4a,b) . Accumulation of macrophages was decreased in cilnidipine-treated mice compared with vehicle-treated mice ( Supplementary Fig.  S4c,d ). (Fig. 7a,b) . We also found that nifedipine, cilnidipine, or ω -conotoxin plus nifedipine inhibited depolarization-induced [Ca 2+ ] i in cultured podocytes (Fig. 7c,d ). These results suggest that both N-type and L-type calcium channels are expressed in cultured human podocytes and are relevant to depolarization-induced [Ca 2+ ] i increase. To confirm the effect of N-type calcium channel blockade on podocytes, we examined the changes in nephrin expression in cultured human podocytes treated with ω -conotoxin. Administration of exogenous TGF-β resulted in a decreased expression of nephrin in podocytes (Fig. 7e) . This decrease was significantly reversed by pre-incubation with ω -conotoxin (Fig. 7e) . Nitrendipine did not change the TGF-β -induced reduction of nephrin expression, but cilnidipine upregulated nephrin expression in podocytes (Fig. 7f) .
The Functional Role of N-type Calcium
Finally, we revealed that inhibition of ERK by mitogen-activated kinase kinase (MEK) inhibitor U0126 significantly ameliorated TGF-β -induce reduction of nephrin expression (Fig. 7g) .
Discussion
Investigation of diabetic nephropathy in rodents is rendered difficult partly by the lack of adequate animal models displaying typical diabetic nephropathy 20 . Among these limited mouse models of diabetic nephropathy, db/db mice are one of the most frequently used disease models. Nevertheless, the genetic background plays an important role in developing diabetic nephropathy; e.g., db/db mice on the C57BLKS background exhibit massive proteinuria and mesangial expansion, whereas db/db mice on the C57BL/6J show less severe glomerular and glycemic changes 20, 21 . Knockout mice are mostly generated on the C57BL/6J or 129/SvJ backgrounds 22 . In order to overcome these situations, we backcrossed Ca v 2.2 knockout mice on the C57BL/6J background with C57BLKS to explore the role of the N-type calcium channel in diabetic nephropathy.
The present study demonstrated that glycemic control was improved with enhanced insulin secretion in diabetic mice by ablation of the N-type calcium channel. In a previous study, Ca v 2.2 −/− mice showed lower fasting glucose levels and better glucose tolerance than wild-type mice without any change in insulin sensitivity upon GTTs 23 . The same study reported that, after 10 weeks of high-fat diet feeding, Ca v 2.2 −/− mice still showed lower fasting glucose levels and better glucose tolerance than Ca v 2.2 +/+ and Ca v 2.2 +/− mice. The mechanisms how Ca v 2.2 deletion resulted in better glycemic control have not been clarified yet, but another report has shown that the N-type calcium channel is present on pancreatic α cells and that GLP-1 inhibits glucagon release by selectively suppressing this channel 24 . In our study, db/db Ca v 2.2 +/− mice showed a marginally improved glucose tolerance; however, the reduction in urinary albumin excretion was much larger than expected from the degree of glycemic control, suggesting that mechanisms other than the amelioration in glucose metabolism would contribute to renoprotective effects, particularly in db/db Ca v 2.2 +/− mice. Diabetic Ca v 2.2 −/− mice showed lower SBP with a marked reduction in urinary catecholamine levels. Similarly, a previous report showed that Ca v 2.2 −/− mice exhibited lower SBP than control mice because of vasodilatation, reduction of heart contractile activity, and inhibition of sympathetic nerve activity 25 . Most notably in our study, urinary albumin excretion was reduced by 70% and renal hyperfiltration was normalized in db/db Ca v 2.2 −/− mice. In addition, even diabetic Ca v 2.2 +/− mice, in which the expression of the N-type calcium channel is ~50% less than wild-type mice, showed a decrease in albuminuria to the level comparable to that in diabetic Ca v 2.2 −/− mice. The former denied reduction in sympathetic nerve activity, suggesting that partial inhibition of the N-type calcium channel could ameliorate albuminuria without affecting sympathetic nerve function.
Cilnidipine has been shown to ameliorate glomerular hypertrophy by dilating both afferent and efferent arterioles in the kidney 12, 16 , and L-type calcium channel blockade does not improve glomerular hypertension because the L-type calcium channel blockade mainly dilates afferent arterioles 15 . Because N-type calcium channels exist at synaptic nerve endings 26 in both the afferent and efferent arterioles, and the blockade of the N-type calcium channel inhibits norepinephrine release 26 , such sympatholytic effect of the N-type calcium channel ablation may have worked to ameliorate glomerular injury in our study. Cilnidipine showed similar antihypertensive effects and suppression of proteinuria both in innervated and denervated spontaneous hypertensive rat (SHR) 27 , thus suggesting that renal sympathetic nerves may have a limited contribution to its renoprotective effects. In our study, albuminuria as well as glomerular histological changes were significantly alleviated in db/db Ca v 2.2 +/− mice and cilnidipine-treated diabetic mice without reduction of urinary catecholamine levels, further providing a possibility for mechanisms independent of the sympathetic nerve activity. In addition, we showed no compensatory expression of α 1 subunits of L-and T-type calcium channel in Ca v 2.2 heterozygous or knockout mice. Further study is necessary to distinguish the effects of N-and T-type calcium channel blocker, because blockade of T-/L-type calcium channel by manidipine 28 or efonidipine 29 exhibit similar effects as N-/L-type calcium channel blocker, cilnidipine, in terms of amelioration of glomerular hypertension.
As diabetic N-type calcium channel knockout mice improved metabolic parameters including glycemic control and blood pressure, the amelioration of diabetic renal injury in N-type calcium channel knockout mice is partly due to simultaneous improvements of metabolic parameters. However, in addition to these actions, we showed possible functional roles of the N-type calcium channel in podocytes. Previous reports showed that glomerular podocytes express the N-type calcium channel 13, 27 . Fan et al. demonstrated the immunoreactivity of N-type calcium channels in kidney vascular walls, possibly in the nerves in adventitia, distal tubules, and podocytes, and that the N-type calcium channel in cultured podocytes was involved in the angiotensin II-induced production of reactive oxygen species 13 . In the present study, we also found that the N-type calcium channel is expressed in glomeruli, presumably podocytes, in control mice. The genetic inhibition of N-type calcium channels reduced podocyte injury in diabetic mice. In vitro analysis using calcium imaging revealed that N-type calcium channels as well as L-type calcium channels are functional in depolarization-induced [Ca 2+ ] i increase in cultured human podocytes. Furthermore, we examined the changes in nephrin expression induced by TGF-β stimulation in cultured human podocytes and revealed that the decrease caused by the administration of exogenous TGF-β was canceled by pre-incubation with ω -conotoxin, cilnidipine or MEK inhibitor. High glucose-induced ERK activation in podocytes is closely associated with diabetic nephropathy through the protein kinase C pathway 30, 31 , suggesting that ERK plays an important role in TGF-β -induced podocyte injury.
In conclusion, we have demonstrated that the ablation or blockade of the N-type calcium channel in diabetic mice exerts renoprotective effects, which effects may be brought about by both improvement of metabolic parameters and protection from podocyte injury. These results indicate that the N-type calcium channel works as an aggravating factor in a mouse model of diabetic nephropathy, suggesting a possibility that the N-type calcium channel should provide a promising therapeutic target for preventing the progression of diabetic nephropathy in humans. 32 . Urine samples were collected using metabolic cages every 2 weeks for measurement of creatinine and albumin 28 . Thereafter, mice were sacrificed at 16 weeks of age. Nitrendipine (15 mg/kg/day; a gift from Tanabe Mitsubishi pharmaceutical company), cilnidipine (15 mg/kg/ day; a gift from Mochida pharmaceutical company) or vehicle were mixed with powdered food at 150-187.5 μ g/g, the concentration of which is adjusted by weekly food intake. CCBs were administered to db/db Ca v 2.2 +/+ mice from 9 weeks to 16 weeks of age.
Methods
Blood and urine parameter measurements. Serum and urinary creatinine levels were assayed by an enzymatic method (SRL, Tokyo, Japan) 32 . Blood glucose was measured with Gunze Life Check (Gunze, Tokyo, Japan) 33 . Plasma insulin levels were measured by enzyme immunoassay (Ultra-sensitive PLUS mouse insulin kit, Morinaga, Yokohama, Japan) 34 . For GTTs, after 16-h fasting, db/+ mice and db/db mice received ip injections with 2 or 1 g/kg glucose, respectively 34 . For insulin tolerance tests (ITTs), after 16-h fasting, db/+ mice and db/db mice received ip injections with 0.4 and 2 units/kg human insulin (Novo Nordisk, Bagsvaerd, Denmark), respectively 34 . We measured catecholamines in 24-h urine by adding 1 mL 6N HCl per 100 ml of urine. Urinary catecholamine contents were measured by high-performance liquid chromatography (SRL, Tokyo, Japan). Urinary albumin was measured with murine albumin enzyme-linked immunosorbent assay (ELISA) kit (Exocell, Philadelphia, PA) 32 . HbA1c values were determined as described previously 33 .
Renal histology, immunohistochemistry, and electron microscopy. Histologic and immunohistochemical examinations were performed as described previously 32 . Immunofluorescence analyses for nephrin and podocin were performed as described previously 32 . Immunohistochemical studies for phospho-ERK and Mac2 (also known as lectin galactoside-binding soluble 3, LGALS3) were performed as described 19, 32 . For the double immunohistochemical study for Wilms' tumor factor-1 (WT1) and Ca v 2.2, kidney sections were fixed with Brasil's fixative. Sections were boiled for 10 min for antigen retrieval. After blocking, sections were incubated with both goat anti-WT-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit anti-Ca v 2.2 antibody (Alomone Labs, Jerusalem, Israel) for 1 h at room temperature. Then, sections were incubated with alkaline phosphatase-conjugated anti-goat IgG and peroxidase-conjugated anti-rabbit IgG (Jackson ImmunoResearch, responses in human podocyte (n = 20-30). (c) Averaged time courses of depolarization-induced Ca 2+ response in human podocyte. 3 μ M nifedipine; black squares, 3 μ M cilnidipine; black circles, 3 μ M ω -conotoxin + 3 μ M nifedipine; white circles, DMSO; white squares. (d) The bars represent the differences between the maximum of ratio and the value of steady state. * p < 0.05, * * p < 0.01, * * * p < 0.001 vs. DMSO. (e) TGF-β 1 (20 ng/ ml) suppressed NPHS1 expression in cultured human podocytes. Its inhibition was canceled by 100 nM ω -conotoxin. n = 11 for TGF-β (− ) groups and n = 12 for TGF-β (+ ) groups. (f) Cilnidipine (10 μ M) not nitrendipine (10 μ M) ameliorated reduction of NPHS1 expression induced by 5 ng/ml TGF-β 1 in podocytes. Vehicle (n = 5) and other groups (n = 6, each). * p < 0.05, * * p < 0.01. GAPDH was used as control.
West Grove, PA) for 1 h. Electron microscopy analysis was performed as described previously 32 . The GBM thickness was measured with the Image J software (Ver 1.45; National Institutes of Health, Bethesda, MD).
Real-time RT-PCR analysis.
Total RNA was extracted using AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Germantown, MD) from glomeruli that were isolated by the graded sieving method 32 . Quantitative real-time PCR was performed using Premix Ex Taq (Takara Bio, Otsu, Japan) on the StepOnePlus system (Applied Biosystems, Foster City, CA) as described previously 35 . Glomerular expression of Tgfb1, Ctgf, Col4a3, Cacna1b, Cacna1c, Cacna1g, Fn1 and Col1a1 mRNA was evaluated. Some of primers and probe sets were described elsewhere 32 and as follows: Cacna1b forward primer, 5′ -gagactccaggggctgacac-3′ ; Cacna1b reverse primer, 5′ -cgttcagtggcctcctccg-3′ ; Cacna1b probe, 5′ -FAM-cagtagacgtcaccaccggcgcg-TAMRA-3′ ; Cacna1c forward primer, 5′ -agactgagtctgtcaacactga-3′ ; Cacna1c reverse primer, 5′ -ggagatccgatgggcaagc-3′ ; Cacna1c probe, 5′ -FAM-ttctccctcgatgtcacctccagcca-TAMRA-3′ ; Cacna1g forward primer, 5′ -ccgagagatccctaggacaca-3′ ; Cacna1g reverse primer, 5′ -gtgtctgctggttgggagtg-3′ ; Cacna1g probe, 5′ -FAM-cccaaagcccagtcaggctccatctt-TAMRA-3′ . Expression of each mRNA was normalized with GAPDH mRNA (TaqMan rodent GAPDH control reagents; Applied Biosystems).
Cell culture. Conditionally immortalized human podocytes were cultured as described previously 36, 37 . Differentiated podocytes were serum-starved for 24 h and then pretreated with 100 nM ω -conotoxin (Peptide Institute, Osaka, Japan) 38 , 10 μ M cilnidipine or 10 μ M nitrendipine at 1 h before the stimulation of recombinant human TGF-β 1 (R&D Systems, Minneapolis, MN). Cells were harvested after 24 h, and the expression level of nephrin was assayed by real-time RT-PCR analysis (n = 5-12).
Calcium imaging. Calcium imaging was performed as described previously with some modification 39 . Human podocyte cells were plated onto poly-L-lysine-coated glass coverslips and subjected to measurement 3-16 h after plating on the coverslips. The cells on coverslips were loaded with fura-2 in RPMI 1640 containing 1 μ M fura-2-acetoxymethyl ester (fura-2-AM; Dojindo Laboratories, Kumamoto, Japan), 10% fetal bovine serum (Sigma), 10 μ g/mL insulin, 5.5 μ g/mL transferrin, 5 ng/mL selenium (Sigma), 30 units/mL penicillin, and 30 μg/ mL streptomycin at 37 °C for 30 min. The coverslips were then plated in a perfusion chamber mounted on the stage of the microscope. The fura-2 fluorescence images of the cells were recorded in HEPES-buffered saline (HBS, 2 mM Ca 2+ ) (in mM): 107 NaCl, 6 KCl, 1.2 MgSO 4 , 2 CaCl 2 , 1.2 KH 2 PO 4 , 11.5 glucose, and 20 HEPES (pH 7.4 adjusted with NaOH). Four minutes after image acquisition, the cells were stimulated with 107 mM K + solution (in mM): 107 KCl, 6 NaCl, 1.2 MgSO 4 , 2 CaCl 2 , 1.2 KH 2 PO 4 , 11.5 glucose, and 20 HEPES (pH 7.4 adjusted with NaOH). All the reagents dissolved in water or dimethylsulfoxide were diluted to their final concentrations and applied to the cells by perfusion. Fluorescence images of the cells were recorded and analyzed with a video image analysis system (AQUACOSMOS; Hamamatsu Photonics, Shizuoka, Japan). The ratio of the fluorescence intensity at 340 nm to the intensity at 380 nm was calculated to evaluate the change in intracellular calcium levels.
Statistical analysis.
Data are expressed as the mean ± SEM. Statistical analysis was performed using one-way ANOVA. P < 0.05 was considered statistically significant.
